Published in Nat Rev Cardiol on June 10, 2014
Venous thromboembolism. 30-year risk of death after VTE. Nat Rev Cardiol (2014) 1.71
Global burden of cardiovascular disease. Nat Rev Cardiol (2013) 0.89
Interventional cardiology: DREAMS of a bioabsorbable stent coming true. Nat Rev Cardiol (2013) 0.83
Vascular disease: Even low-risk individuals can benefit from statin therapy. Nat Rev Cardiol (2012) 0.81
Device therapy. Comorbidity is a major predictor of pacemaker safety in the elderly. Nat Rev Cardiol (2013) 0.80
Transplantation: Ex vivo perfusion of human hearts--implications for donor organ availability. Nat Rev Cardiol (2015) 0.78
Risk factors: Depression recognized as a risk factor in ACS. Nat Rev Cardiol (2014) 0.77
Heart failure: rolofylline fails to improve renal function in patients with acute HF. Nat Rev Cardiol (2011) 0.76
Lipids. Dalcetrapib raises HDL-cholesterol level, but does not reduce cardiac risk. Nat Rev Cardiol (2012) 0.76
Drug-eluting stents in ischaemic peripheral artery disease. Nat Rev Cardiol (2012) 0.76
FFR-guided revascularization versus medical therapy-the debate goes on. Nat Rev Cardiol (2012) 0.76
Hypertension. Cardiac effects of renal denervation. Nat Rev Cardiol (2012) 0.76
Risk factors: CVD risk and the 'obesity paradox'. Nat Rev Cardiol (2015) 0.76
Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial. Nat Rev Cardiol (2011) 0.76
Atherosclerosis: Addition of niacin to optimal statin therapy does not affect plaque regression. Nat Rev Cardiol (2013) 0.76
Obesity: Benefits of bariatric surgery. Nat Rev Cardiol (2012) 0.75
Valvular disease: TAVI safe and effective for patients with a bicuspid aortic valve. Nat Rev Cardiol (2013) 0.75
Interventional cardiology: optimal repair of ruptured abdominal aortic aneurysms. Nat Rev Cardiol (2014) 0.75
Interventional cardiology: Hydration reduces angiographic AKI. Nat Rev Cardiol (2011) 0.75
Vascular disease: lowering LDL cholesterol reduces atherosclerotic risk in patients with chronic kidney disease. Nat Rev Cardiol (2011) 0.75
Surgery: predicting acute type B aortic dissection-size does not matter. Nat Rev Cardiol (2011) 0.75
Infection: Myocardial disease in patients with HIV. Nat Rev Cardiol (2013) 0.75
Anticoagulation therapy: Idrabiotaparinux noninferior to warfarin for long-term treatment of pulmonary embolism. Nat Rev Cardiol (2011) 0.75
Arrhythmias. Refined programming accentuates the benefits of ICDs. Nat Rev Cardiol (2012) 0.75
Intra-aortic balloon support for MI and cardiogenic shock--time to change the guidelines? Nat Rev Cardiol (2012) 0.75
Vascular disease: Ramipril improves walking times in patients with PAD. Nat Rev Cardiol (2013) 0.75
Hypertension: Salt restriction might lower blood pressure, but are there any beneficial effects on mortality? Nat Rev Cardiol (2011) 0.75
Heart failure: Lixivaptan reduces volume overload in patients with heart failure. Nat Rev Cardiol (2012) 0.75
Venous thromboembolism. Aspirin ASPIREs to reduce vascular events after VTE. Nat Rev Cardiol (2012) 0.75
Anticoagulation therapy: Apixaban is cost-effective. Nat Rev Cardiol (2014) 0.75
Biomarkers: Predictors of CVD risk in the elderly. Nat Rev Cardiol (2012) 0.75
Valvular disease: Aortic valve-in-valve replacement. Nat Rev Cardiol (2012) 0.75
Pharmacotherapy: β-Blocker therapy before PCI for STEMI reduces infarct size. Nat Rev Cardiol (2013) 0.75
Diabetes: Cardiovascular safety of 'gliptin' therapy. Nat Rev Cardiol (2013) 0.75
Risk factors: intestinal microbiota: "a new direction in cardiovascular research". Nat Rev Cardiol (2013) 0.75
Venous thromboembolism: High incidence of bleeding with fibrinolysis in intermediate-risk pulmonary embolism. Nat Rev Cardiol (2014) 0.75
Coronary artery disease: Antidepressant treatment for mental stress-induced myocardial ischaemia. Nat Rev Cardiol (2013) 0.75
Hypertension: Vitamin D supplementation lacks benefit in systolic hypertension. Nat Rev Cardiol (2013) 0.75
Hypertension: Benefits of combined therapy. Nat Rev Cardiol (2014) 0.75
Cardiovascular diseases after the Great East Japan Earthquake. Nat Rev Cardiol (2012) 0.75
Risk factors: Mechanistic insights into the cardiovascular benefits of a Mediterranean diet. Nat Rev Cardiol (2014) 0.75
Coronary artery disease: IL-6 signaling linked with CHD. Nat Rev Cardiol (2012) 0.75
Device therapy. Meta-analysis demonstrates safety of pacemaker reutilization. Nat Rev Cardiol (2011) 0.75
Acute coronary syndromes: Thrombin-receptor antagonist increases bleeding in patients with ACS. Nat Rev Cardiol (2011) 0.75
Device therapy: Public-access AEDs improve neurologically intact survival after cardiac arrest. Nat Rev Cardiol (2011) 0.75
Heart failure: Study sheds light on importance of vitamin D in patients with HF. Nat Rev Cardiol (2012) 0.75
Identifying silent heart disease. Nat Rev Cardiol (2012) 0.75
Pharmacotherapy: No link found between statins and risk of cancer. Nat Rev Cardiol (2011) 0.75
Pharmacotherapy. Elevating HDL-cholesterol levels with dalcetrapib is safe. Nat Rev Cardiol (2012) 0.75
Interventional cardiology: Anticoagulation during AF ablation. Nat Rev Cardiol (2014) 0.75
Anticoagulation therapy: New score for hemorrhage risk. Nat Rev Cardiol (2011) 0.75
Vascular disease: Exercise outperforms stenting for claudication in patients with aortoiliac PAD. Nat Rev Cardiol (2011) 0.75
Coronary artery disease: Similar 5-year outcomes with CABG surgery or PCI for left main disease. Nat Rev Cardiol (2014) 0.75
Interventional cardiology: Variation in cardiac catheterization--implications for patient care. Nat Rev Cardiol (2013) 0.75
Acute coronary syndromes: Using chest pain to diagnose acute MI. Nat Rev Cardiol (2013) 0.75
Vascular disease: No added benefit of niacin with statins. Nat Rev Cardiol (2011) 0.75
Acute coronary syndromes: higher mortality after acute MI in the UK than in Sweden. Nat Rev Cardiol (2014) 0.75
Hypertension: First-in-class agent lowers BP. Nat Rev Cardiol (2011) 0.75
Interventional cardiology: Causes of death after PCI. Nat Rev Cardiol (2014) 0.75
Surgery: No benefit of acadesine in CABG. Nat Rev Cardiol (2012) 0.75
Risk factors: Air pollution and cardiovascular risk during the Beijing Olympics. Nat Rev Cardiol (2012) 0.75
Device therapy: New centrifugal pump noninferior. Nat Rev Cardiol (2012) 0.75
Sex-dependent cardiovascular risk. Nat Rev Cardiol (2012) 0.75
Risk factors: "Looking old for your age" increases cardiovascular risk. Nat Rev Cardiol (2014) 0.75
Acute coronary syndromes: Reduced mortality from MI in Denmark, England, and Poland. Nat Rev Cardiol (2012) 0.75
Exercise or medication keeps patients with coronary heart disease UPBEAT. Nat Rev Cardiol (2012) 0.75
Venous thromboembolism: Edoxaban: as effective and safer than warfarin in VTE. Nat Rev Cardiol (2013) 0.75
Valvular disease: TAVR is cost-effective in the USA and UK. Nat Rev Cardiol (2012) 0.75
Dyslipidaemia. Fasting before blood lipid testing might be unnecessary. Nat Rev Cardiol (2014) 0.75
Antiplatelet therapy: Treatment with ticagrelor for 12 months after ACS is cost-effective. Nat Rev Cardiol (2012) 0.75
Obesity: Counseling emPOWERs patients to lose weight. Nat Rev Cardiol (2011) 0.75
Heart failure: LCZ696--a PARADIGM shift in treatment for heart failure. Nat Rev Cardiol (2014) 0.75
Hypertension: Riociguat therapy for pulmonary hypertension. Nat Rev Cardiol (2013) 0.75
Stem cells: Myocardial regeneration after infarction-promising phase I trial results. Nat Rev Cardiol (2012) 0.75
Cardiac resuscitation: Potential success of prolonged paediatric CPR. Nat Rev Cardiol (2013) 0.75
Antiplatelet therapy. ARCTIC leaves platelet testing out in the cold. Nat Rev Cardiol (2012) 0.75
Heart failure. Drugs outperform ultrafiltration in acute cardiorenal syndrome. Nat Rev Cardiol (2012) 0.75
Anticoagulation therapy: Direct factor Xa inhibition improves stroke prevention in patients with AF. Nat Rev Cardiol (2011) 0.75
Stem cells: Do fetal cells repair maternal hearts? Nat Rev Cardiol (2011) 0.75
Improved survival rates possible after prolonged resuscitation attempts. Nat Rev Cardiol (2012) 0.75
Heart failure: Cardiac myosin activator shows promise in phase II trial. Nat Rev Cardiol (2011) 0.75
Hypertension: Treprostinil therapy for PAH. Nat Rev Cardiol (2013) 0.75
Public health. Quantifying the global burden of ischaemic heart disease. Nat Rev Cardiol (2014) 0.75
Heart failure: Drugs outperform ultrafiltration in acute cardiorenal syndrome. Nat Rev Nephrol (2012) 0.75
Interventional cardiology: Streamlining reperfusion for STEMI. Nat Rev Cardiol (2013) 0.75
Antiplatelet therapy. Intracoronary abciximab during PCI for STEMI. Nat Rev Cardiol (2012) 0.75
Antiplatelet therapy: Discontinuation of low-dose aspirin reverses its prophylactic effect. Nat Rev Cardiol (2011) 0.75
Risk factors. Childhood exposure to parental smoking confers lifelong increase in cardiovascular risk. Nat Rev Cardiol (2014) 0.75
Venous thromboembolism: Increased embolic risk from combined oral contraceptives. Nat Rev Cardiol (2011) 0.75
Prevention: Polypills reduce CVD risk factors. Nat Rev Cardiol (2012) 0.75
Risk factors: Vitamin D level and surgical risk. Nat Rev Cardiol (2013) 0.75
Intervention: Logistic Clinical SYNTAX score. Nat Rev Cardiol (2012) 0.75
Valvular disease: implications of new-onset conduction abnormalities after TAVI. Nat Rev Cardiol (2014) 0.75
Acute coronary syndromes: Postconditioning reduces myocardial edema. Nat Rev Cardiol (2012) 0.75
Risk factors: First statement on sexual activity in patients with cardiovascular disease. Nat Rev Cardiol (2012) 0.75
Diabetes: Does glycemic control reduce cardiovascular event rates? Nat Rev Cardiol (2012) 0.75
Arrhythmias: Control rhythm rather than rate to delay permanent AF. Nat Rev Cardiol (2011) 0.75
Lipids: atherosclerosis begins "shortly after birth" in children with FH. Nat Rev Cardiol (2013) 0.75
Vascular disease: Peripheral artery disease pandemic. Nat Rev Cardiol (2013) 0.75
Dyslipidaemia. Implications of new statin guidelines. Nat Rev Cardiol (2014) 0.75